Abstract:You have accessJournal of UrologyCME1 May 2022MP06-09 SINGLE CELL ANALYSES OF MURINE UROTHELIAL CARCINOMA CELLS REVEAL A ROLE OF TUMOR-ASSOCIATED MACROPHAGES IN RESPONSE TO ANTI-PD1 THERAPY Dongbo Xu, Li Wang, Yali Zhang, Yanqing Wang, Xiaojing Zhang, Yue Wu, Gary Smith, Bo Xu, Prashant Singh, Yuesheng Zhang, David Goodrich, Jianmin Wang, and Qiang Li Dongbo XuDongbo Xu More articles by this author , Li WangLi Wang More articles by this author , Yali ZhangYali Zhang More articles by this author , Yanqing WangYanqing Wang More articles by this author , Xiaojing ZhangXiaojing Zhang More articles by this author , Yue WuYue Wu More articles by this author , Gary SmithGary Smith More articles by this author , Bo XuBo Xu More articles by this author , Prashant SinghPrashant Singh More articles by this author , Yuesheng ZhangYuesheng Zhang More articles by this author , David GoodrichDavid Goodrich More articles by this author , Jianmin WangJianmin Wang More articles by this author , and Qiang LiQiang Li More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002523.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Approximately 80% of patients with advanced bladder cancer do not respond to immune checkpoint inhibitor (ICI) immunotherapy. The molecular mechanism of ICI treatment response remains unknown largely due to the lack of clinically relevant immunocompetent mouse models. METHODS: We developed a syngeneic triple knockout (TKO: Trp53/Pten/Rb1) bladder cancer model in immunocompetent C57 BL/6J mice. Mouse urothelial cells (Trp53f/f, Ptenf/f, Rb1f/f) were transfected ex vivo with Ad5CMVCre (Adenovirus Cre recombinase driven by a CMV promoter). The TKO urothelial cells were subcutaneously injected into immunocompetent C57 BL/6J for tumor formation. The tumors were treated with an anti-PD1 antibody (BioXcell, RMP1-14, 200 μg, intraperitoneally twice weekly) (n=9) or a control IgG (n=9). Single cell analyses were performed for tumor xenografts from control IgG (n=2), responders (30% less than the median of control tumors) (n=2) and non-responders (n=2) using PTPRC (also named CD45) expression as an immune cell marker. Seurat package was used for data analysis including dimension reduction, cell clustering, and identification of cell markers. SingleR package was utilized to identify the cell types. Immunohistochemistry (IHC) of CD8 and F4/80 was performed to identify T cells and macrophages respectively. RESULTS: Anti-PD-1 immunotherapy resulted in a mixed pattern of treatment responses in individual tumors. Eight clusters of immune cells were identified (basophils, B cells, dendritic cells, macrophages, monocytes, neutrophils, NK cell, and T cells) in ICI treated xenografts. Responder xenografts displayed significantly increased immune cell infiltration (15.2%, 742 immune cells/4861 total cells) compared to the non-responder tumors (10.1%, 452 immune cells/4459 total cells, Fisher Exact Test p<0.0001). Specifically, there were more T cells (46/4861 vs 18/4459, p=0.002), and macrophages (420/4861 vs 287/4459, p=0.002) in responder xenografts than in non-responder xenografts. Compared to control IgG tumors, a near complete response tumor exhibited an immune-inflamed phenotype with significant infiltration of T cells and macrophages, whereas non-responder tumors showed no significant change of T cells and macrophages infiltration. CONCLUSIONS: The higher percentage of T cells and macrophages tumor infiltration in responders suggests a potential role of innate immune microenvironment for the ICI treatment response. Modulating tumor associated macrophage may overcome the resistance to ICI immunotherapy. Source of Funding: This research work was supported in part by NIH Grants, K08CA252161(Li, Q), P30CA016056 (NCI Cancer Center Core Support Grant), the Roswell Park Alliance Foundation and the Friends of Urology Foundation © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e80 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Dongbo Xu More articles by this author Li Wang More articles by this author Yali Zhang More articles by this author Yanqing Wang More articles by this author Xiaojing Zhang More articles by this author Yue Wu More articles by this author Gary Smith More articles by this author Bo Xu More articles by this author Prashant Singh More articles by this author Yuesheng Zhang More articles by this author David Goodrich More articles by this author Jianmin Wang More articles by this author Qiang Li More articles by this author Expand All Advertisement PDF DownloadLoading ...

Usp 18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-l and elevated secretion of Cxcl 10

Usp18 Deficient Mammary Epithelial Cells Create an Antitumour Environment Driven by Hypersensitivity to IFN‐λ and Elevated Secretion of Cxcl10

Plenary Paper

Tumor-initiating Stem Cell Shapes Its Microenvironment into an Immunosuppressive Barrier and Pro-Tumorigenic Niche.

S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy

Identification of Potential Therapeutic Targets among CXC Chemokines in Breast Tumor Microenvironment Using Integrative Bioinformatics Analysis

Cancer cells impair monocyte-mediated T cell stimulation to evade immunity

Abstract 5554: Breast cancer with different chemosensitivity has distinct influence on the immune microenvironment

Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment

The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody

Identifying potential immuno-oncology targets in salivary gland mucoepidermoid carcinoma based on inflammatory status and treatment response

Non-small Cell Lung Cancer Cells Modulate the Development of Human CD1c+ Conventional Dendritic Cell Subsets Mediated by CD103 and CD205

Modulation of Gene Expression in MHCC97 Cells by Interferon Alpha

Insufficient CD100 shedding contributes to suppression of CD8+ T-cell activity in non-small cell lung cancer

MicroRNAs 15A and 16–1 Activate Signaling Pathways That Mediate Chemotaxis of Immune Regulatory B Cells to Colorectal Tumors

Interleukin-10 overexpression in 4T1 cells: A gateway to suppressing mammary carcinoma growth

SERS Analysis Of Sialic Acid In Single Dendritic Cells Within The Tumor Microenvironment

Tenascin-C Orchestrates an Immune-Suppressive Tumor Microenvironment in Oral Squamous Cell Carcinoma

MA09.10 Paired Specimens Elucidate the Role of Tumor Microenvironment Reprogramming in the Efficacy of Neoadjuvant Chemoimmunotherapy in NSCLC

Spatially organized multicellular immune hubs in human colorectal cancer

MP06-09 SINGLE CELL ANALYSES OF MURINE UROTHELIAL CARCINOMA CELLS REVEAL A ROLE OF TUMOR-ASSOCIATED MACROPHAGES IN RESPONSE TO ANTI-PD1 THERAPY